Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3145)	6/2/1999 10:18:00 AM
From: dalroi	Read Replies (1) \| Respond to of 10280

additional info on sepr UCB deal what i write here i read in our local fin newspaper in belgium deal is structured as follows as patent rights in europe are finisched in 2002 UCB has bought rights on sepr improved version of zyrtec BUT ONLY IN EUROPE on a royaltie base if sale rise royalties go up also (at least thats what i make out of it) UCB didnt buy US and JAPAN rights as there patent is valid till 2007 i think One should know that price of ucb shares exploded 8-10* in a few years due to admission of zyrtec in us So i realy find this a clever deal on the part of SEPR 1/ royalties on euro sales 2/ rapid penetration in euro with a/ ideal test population , if something goes wrong well its only europe b/ if it works here it will work in the us i only find it a disappointment UCB didnt buy SEPR If any of you wanna buy UCB dont UCB is controled by 2 holding Fin d' obourg and fin tubize which is at a 25% cheaper per share also listed on brussels exchange simply to make thing a bit cloudy for the us citizens DALROI